AYTU Stock Analysis: Buy, Sell, or Hold?
AYTU - AYTU BioPharma, Inc. Common Stock
$2.25
0.02 (0.90%)
▲
5d:
+9.22%
30d:
+4.17%
90d:
-13.79%
SELL
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Sep 22, 2026
Get Alerted When AYTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⚠️ CAUTION: AYTU is extended with warning signals. Consider taking profits or waiting for better entry.
⚠️ CAUTION: AYTU is extended with warning signals. Consider taking profits or waiting for better entry.
In-depth Analysis How we analyze
Valuation Analysis: AYTU is currently trading at $2.25, which is considered extended relative to its 30-day fair value range of $2.13 to $2.22. From a valuation perspective, the stock is trading at a discount (Forward PE: -30.0) compared to its historical average (14.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AYTU is in a strong downtrend. The price is approaching resistance at $2.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AYTU has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.50 (+322.2%). Given the valuation headwinds and technical position, caution is warranted at these levels.
Technical Outlook: Technically, AYTU is in a strong downtrend. The price is approaching resistance at $2.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AYTU has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.50 (+322.2%). Given the valuation headwinds and technical position, caution is warranted at these levels.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.13 -
$2.22
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
33.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 322.2% below Wall St target ($9.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$2.13 -
$2.22
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.03
Resistance Level
$2.28
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-30.00
Wall Street Target
$9.50
(+322.2%)
Revenue Growth (YoY)
-32.7%
Profit Margin
-60.2%
PE vs Historical
-30.0 vs 14.8
CHEAP
Share & Embed Analysis
Last updated: August 03, 2026 7:56 PM ET
Data refreshes hourly during market hours. Next update: 8:56 PM
Data refreshes hourly during market hours. Next update: 8:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AYTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
